Jeffrey Fenyves
Gastroenterology · Kingsport, TNNPI 1700887106
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $10,540 of the $14,209 with a category attached, or 74.2%. 18 manufacturers reported payments, led by Takeda Pharmaceuticals U.S.A., Inc. at 48.8% of the total. Reporting peaked in 2020 at $7,239 and has fallen 98.5% since, to $109 in 2022.
Across 267 payments — averaging $53.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$7K
- AbbVie$5K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
- Ironwood Pharmaceuticals, Inc$249
- Pfizer$187
- Intercept Pharmaceuticals, Inc.$174
- plus $670 from 12 others
Across 8 payments — averaging $2958.81 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$17K
- Pfizer$7K
What the payments were for
- Speaking & faculty fees$10,54074%
- Travel & lodging$370%
- Food & beverage$3,62626%
- Education$70%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 46 | $6,941 |
| AbbVie(2 entities) | 36 | $4,751 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 97 | $1,237 |
| Ironwood Pharmaceuticals, Inc | 19 | $249 |
| Pfizer | 18 | $187 |
| Intercept Pharmaceuticals, Inc. | 11 | $174 |
| Daiichi Sankyo Inc. | 6 | $120 |
| Johnson & Johnson | 7 | $115 |
| QOL Medical, LLC | 6 | $91 |
| Gilead | 5 | $91 |
| Concordia Pharmaceuticals Inc. | 3 | $63 |
| Nestle Healthcare Nutrition Inc. | 3 | $47 |
| Braintree Laboratories, Inc. | 2 | $41 |
| Merck | 2 | $33 |
| Romark Laboratories, LC | 3 | $29 |
| Ferring Pharmaceuticals Inc. | 1 | $14 |
| UCB, Inc. | 1 | $13 |
| Redhill Biopharma Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,209 in reported general payments places this provider in the 85th percentile of 336 gastroenterology providers in Tennessee.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LinzessLinaclotide | 12 | $7,620 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess | $4,751 | $7,62012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 336 gastroenterology providers in Tennessee.
Other gastroenterology in Kingsport
- David SchwartzNashville$1.3M
- Ziad YounesGermantown$1M
- Dawn Borromeo BeaulieuNashville$421K
- Satheesh NairMemphis$349K
- Colin HowdenMemphis$291K
- Sara HorstNashville$246K
- Raj NarayaniKnoxville$204K
- Chakradhar ReddyJohnson City$161K
- Leonard BaidooMemphis$152K
- William LylesMaryville$151K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.